Drugs Containing Excipient (Inactive Ingredient) ACRYLIC ACID/SODIUM ACRYLATE COPOLYMER

Branded drugs containing ACRYLIC ACID/SODIUM ACRYLATE COPOLYMER excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Galderma Laboratories LP	EPIDUO FORTE	adapalene and benzoyl peroxide	0299-5906	ACRYLIC ACID/SODIUM ACRYLATE COPOLYMER
Galderma Laboratories LP	AKLIEF	trifarotene	0299-5935	ACRYLIC ACID/SODIUM ACRYLATE COPOLYMER	2031-07-19

Generic drugs containing ACRYLIC ACID/SODIUM ACRYLATE COPOLYMER excipient

Company	Ingredient	NDC	Excipient
Galderma Laboratories LP	adapalene and benzoyl peroxide	0299-5906	ACRYLIC ACID/SODIUM ACRYLATE COPOLYMER
Galderma Laboratories LP	trifarotene	0299-5935	ACRYLIC ACID/SODIUM ACRYLATE COPOLYMER
Alembic Pharmaceuticals Limited	adapalene and benzoyl peroxide topical	46708-662	ACRYLIC ACID/SODIUM ACRYLATE COPOLYMER

Acrylic Acid/Sodium Acrylate Copolymer Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 18, 2026

Acrylic acid/sodium acrylate copolymer is primarily a superabsorbent polymer rather than a conventional oral pharmaceutical excipient. Its commercial economics are driven by hygiene products, wound care, medical absorbents, and industrial water-management applications. Pharmaceutical demand is smaller and specification-heavy, with revenue tied to controlled particle size, residual monomer limits, crosslink density, extractables, biocompatibility, and regulatory documentation.

The market has a positive long-term volume outlook but limited transparency. Public companies generally report this material within broader superabsorbent polymer, specialty chemicals, or hygiene businesses. Standalone pharmaceutical-excipient revenue, market share, and product-level margins are not publicly disclosed.

What is acrylic acid/sodium acrylate copolymer used for in pharmaceuticals?

Acrylic acid/sodium acrylate copolymer is a crosslinked, water-absorbing polymer based on acrylic acid and its sodium salt. In pharmaceutical and medical applications, it can provide fluid absorption, swelling, gel formation, viscosity modification, and moisture control.

Common application areas include:

Application	Functional role	Commercial relevance
Oral solid dosage forms	Swelling, matrix modification, moisture management	Limited and formulation-specific
Wound dressings	Absorption and gel formation	More significant than traditional tablet use
Ostomy and continence products	Fluid retention and odor or moisture control	Commercially important
Topical and transdermal systems	Absorbent or rheology-modifying component	Selective
Medical absorbent pads	Liquid uptake and retention	High relative to oral pharmaceuticals
Controlled-release systems	Swelling polymer or matrix component	Research and niche commercial use
Diagnostic and laboratory products	Fluid capture and retention	Small but technically attractive

The material is often discussed under related names, including sodium polyacrylate, partially neutralized polyacrylic acid, crosslinked sodium polyacrylate, and superabsorbent polymer. These terms are not always interchangeable. Molecular weight, neutralization level, crosslinking, particle size, residual acrylic acid, and intended use determine whether a product is suitable for pharmaceutical or medical applications.

How does it differ from Carbopol and other acrylic polymers?

Acrylic acid/sodium acrylate copolymer should not be treated as identical to carbomer. Carbomers are highly crosslinked polyacrylic acid polymers used primarily as gelling, thickening, and suspending agents. Acrylic acid/sodium acrylate copolymers are generally more strongly associated with absorption and swelling.

Material	Primary function	Typical pharmaceutical use
Acrylic acid/sodium acrylate copolymer	Absorption, swelling, gel formation	Medical absorbents and selected formulation systems
Carbomer	Thickening, suspension, gel formation	Topicals, ophthalmics, oral liquids
Sodium carboxymethylcellulose	Thickening, binding, stabilization	Oral, topical, ophthalmic
Crospovidone	Superdisintegration	Tablets
Sodium starch glycolate	Superdisintegration	Tablets
Polyacrylic acid, sodium salt	Thickening, chelation, absorption	Selected oral, topical, and medical uses

The distinction matters commercially. Carbomer and superdisintegrant markets have clearer pharmaceutical identities, while acrylic acid/sodium acrylate copolymer is often sold into broader absorbent-material markets.

What is the regulatory status of acrylic acid/sodium acrylate copolymer?

The regulatory status depends on the exact chemical identity, grade, route of administration, dosage form, and jurisdiction. FDA’s Inactive Ingredient Database is the primary U.S. reference for determining whether a specific inactive ingredient has precedent in approved drug products. A listing does not create a blanket authorization for every grade or route.

What is the FDA and Orange Book status?

Acrylic acid/sodium acrylate copolymer does not have an Orange Book listing as an active pharmaceutical ingredient. The Orange Book identifies approved drug products, patents, and exclusivity associated with active drug products. It does not generally list excipient patents as standalone Orange Book entries.

For an excipient supplier, the relevant FDA pathway is usually:

1. Establish identity and specifications.
2. Confirm applicable FDA Inactive Ingredient Database precedent.
3. Support the drug master file or sponsor regulatory filing.
4. Provide impurity, residual monomer, extractables, leachables, and toxicology data.
5. Demonstrate batch consistency and manufacturing control.

FDA’s inactive-ingredient framework places practical importance on route-specific precedent, maximum daily exposure, dosage form, and concentration. A material used in a topical dressing may face a different regulatory assessment from the same chemistry proposed for an oral tablet or ophthalmic product.[1]

What pharmacopeial standards apply?

The applicable standard may be a monograph for sodium polyacrylate, polyacrylic acid derivatives, or another recognized polymer category, depending on the product identity. USP-NF, Ph. Eur., and JP coverage must be checked against the supplier’s exact grade and nomenclature. Many commercial grades remain specification-controlled through customer quality agreements rather than a universally harmonized monograph.

Key specifications commonly include:

• Acrylic acid residual monomer
• Sodium content and degree of neutralization
• Molecular-weight distribution
• Particle-size distribution
• Absorption capacity
• Absorption under load
• pH
• Loss on drying or moisture
• Ash and inorganic residues
• Heavy metals and elemental impurities
• Microbial quality
• Extractables and leachables
• Residual solvents and processing aids

How large is the acrylic acid/sodium acrylate copolymer market?

There is no reliable public market-size series for the pharmaceutical-excipient segment alone. Commercial market studies usually combine acrylic-acid superabsorbent polymers with diapers, adult incontinence products, feminine hygiene, medical products, agriculture, and industrial uses.

The relevant economic market is therefore best divided into three layers:

Market layer	Demand profile	Financial importance
Superabsorbent polymers	High-volume hygiene and medical demand	Dominant
Specialty medical grades	Higher specifications and qualification barriers	Attractive margins
Pharmaceutical excipient grades	Small volumes, long qualification cycles	Strategic but not volume-leading

Hygiene products account for the largest consumption base because superabsorbent polymers are used in disposable diapers, adult incontinence products, and feminine hygiene products. Pharmaceutical-grade demand is more fragmented and is often embedded in combination products, dressings, or proprietary delivery systems.

Public disclosures from major chemical producers indicate that superabsorbent polymers are a meaningful specialty-material category, but companies generally do not separate pharmaceutical revenue from hygiene revenue. BASF, Nippon Shokubai, Sumitomo Seika, Evonik, and related producers report at business-unit or product-family level rather than by pharmaceutical-excipient grade.[2-5]

What drives market demand?

Is pharmaceutical demand growing?

Pharmaceutical demand is likely to grow selectively rather than at the rate of the broader superabsorbent polymer market. The strongest demand drivers are:

• Growth in advanced wound care
• Aging populations and increased continence-product use
• Home healthcare and outpatient treatment
• Higher use of disposable medical absorbents
• Interest in low-dose, high-performance swelling materials
• Development of moisture-control systems for drug products
• Demand for latex-free and fiber-reduced absorbent products

The oral pharmaceutical opportunity is narrower. Formulators often prefer established excipients such as crospovidone, croscarmellose sodium, sodium starch glycolate, hypromellose, and carbomer because their regulatory histories and supplier networks are stronger.

Which end markets matter most?

Medical and pharmaceutical applications benefit from higher selling prices but represent a small share of total polymer volume. Hygiene markets provide manufacturing scale and capacity utilization. This creates a two-tier commercial model:

• Commodity or standard superabsorbent grades generate volume.
• Medical and pharmaceutical grades generate differentiation, qualification value, and potentially higher gross margin.

A producer that sells only into pharmaceutical applications may face high customer-concentration risk. A producer with both hygiene and specialty grades can use the large hygiene market to support capacity while pursuing higher-margin medical qualification programs.

What are the key supply-chain and manufacturing barriers?

Manufacturing is based on acrylic acid neutralization, aqueous polymerization, crosslinking, drying, milling, classification, and packaging. The process requires tight control of polymer structure and residual monomer levels.

Which raw materials affect cost?

The major cost inputs are:

• Acrylic acid
• Sodium hydroxide or another neutralizing agent
• Crosslinkers
• Initiators
• Energy for drying and processing
• Packaging
• Waste treatment and quality-control testing

Acrylic acid is a petrochemical derivative. Its price is influenced by propylene economics, refinery and cracker operating rates, regional supply-demand balance, energy prices, and plant outages. Sodium hydroxide costs affect neutralization economics and can be material in high-neutralization products.

What manufacturing constraints affect profitability?

The main constraints are:

1. Acrylic acid supply and price volatility.
2. Energy intensity during drying.
3. Wastewater and residual-monomer control.
4. Qualification of new production sites.
5. Consistency of absorption performance.
6. Contamination control and clean packaging.
7. Capacity allocation between standard and specialty grades.

Pharmaceutical customers may require dedicated production campaigns, validated cleaning, documented change control, and extended stability data. These requirements increase fixed costs and reduce manufacturing flexibility.

How strong is the patent estate for this excipient?

The base chemistry is mature and generally cannot be protected broadly through new composition-of-matter patents. Commercial protection usually comes from narrower claims covering:

• Crosslinker combinations
• Degree of neutralization
• Particle morphology
• Surface treatment
• Absorption under load
• Low residual monomer profiles
• Multilayer or composite structures
• Manufacturing conditions
• Medical-device integration
• Specific wound or absorbent architectures

Patent strength is therefore application-specific. A generic producer may be able to manufacture a conventional sodium polyacrylate-type material, but it may still face process or product-performance patents covering premium absorbent structures.

Patent category	Typical strength	Generic-entry impact
Basic acrylic acid/sodium acrylate composition	Low to moderate	Limited
Crosslinked particle architecture	Moderate	Can block equivalent performance
Low-monomer manufacturing process	Moderate	May require process redesign
Medical dressing combination	Moderate to high	Important for device competition
Pharmaceutical formulation use	Variable	Depends on claim breadth and prior art
Packaging and delivery system	Low to moderate	Usually design-around possible

No single Orange Book patent estate controls the material itself. Freedom-to-operate analysis must examine the intended application, supplier process, formulation, medical device, and jurisdiction.

When does acrylic acid/sodium acrylate copolymer lose exclusivity?

The excipient chemistry does not have one global exclusivity date. Basic composition patents and manufacturing patents expire at different times and vary by country. Many foundational patents covering superabsorbent polymer chemistry are decades old, leaving the base material open to multiple producers.

Current commercial exclusivity is more likely to arise from:

• Proprietary grades
• Trade secrets
• Customer qualification
• Performance specifications
• Regulatory documentation
• Supply agreements
• Process patents
• Medical-device design patents
• Brand and quality reputation

This makes the market less dependent on formal patent expiration than branded pharmaceuticals. The practical barrier to entry is often qualification time rather than patent duration.

Are there Paragraph IV challenges or generic-entry risks?

Paragraph IV litigation is generally not the central competitive mechanism for an excipient. Paragraph IV certifications apply to patents listed in the FDA Orange Book for approved drug products. An excipient supplier does not normally face a standalone Paragraph IV challenge merely because it sells acrylic acid/sodium acrylate copolymer.

Generic-entry risks arise indirectly when the material is incorporated into:

• A branded drug formulation
• A controlled-release product
• A proprietary wound-care product
• A combination medical device
• A drug-device system

In those cases, competitors may challenge formulation, method-of-use, device, or manufacturing patents. The excipient itself may be replaceable if a competing polymer can meet the same performance and regulatory requirements.

Which companies compete in this market?

The competitive field includes large superabsorbent polymer producers, specialty polymer suppliers, and regional manufacturers.

Company	Relevant capability	Competitive position
Nippon Shokubai	Large-scale superabsorbent polymers and acrylic chemistry	Global scale and integrated supply
BASF	Superabsorbent polymer and specialty chemical operations	Broad geographic and technical platform
Sumitomo Seika	Superabsorbent polymers and specialty absorbent materials	Strong Asian manufacturing base
Evonik	Specialty polymers and medical-material capabilities	Stronger in specialty and healthcare-adjacent materials
Lubrizol	Acrylic polymers and pharmaceutical excipients	Strong in carbomers and formulation polymers
Regional specialty suppliers	Custom grades and contract manufacturing	Flexible, but often less globally qualified

The relevant comparison is not only polymer price. Pharmaceutical and medical customers assess quality systems, regulatory support, supply continuity, change-control history, geographic redundancy, and technical service.

What is the financial trajectory for suppliers?

The financial trajectory is likely to show volume resilience but margin volatility.

Base case

Revenue grows at a low- to mid-single-digit rate over the medium term, supported by medical absorbents, continence care, and selective pharmaceutical adoption. Margins fluctuate with acrylic acid and energy costs. Specialty-grade revenue grows faster than standard-grade revenue, but it remains too small to transform the consolidated financial profile of major producers.

Upside case

Profitability improves if suppliers:

• Increase specialty medical-grade penetration.
• Secure multi-year qualification agreements.
• Pass through raw-material inflation.
• Reduce energy use in drying.
• Add regional production redundancy.
• Develop high-absorption or low-monomer grades.
• Move from raw polymer supply into engineered absorbent components.

Downside case

Margins compress if:

• Hygiene demand weakens.
• Acrylic acid prices rise faster than contractual pass-through.
• New Asian capacity increases supply.
• Customers dual-source aggressively.
• Regulatory requirements increase testing costs.
• Buyers substitute cellulose, modified starch, or other absorbent materials.

Financial variable	Expected direction	Main determinant
Volume	Positive over the long term	Hygiene and medical demand
Average selling price	Mixed	Product mix and raw-material pass-through
Gross margin	Volatile	Acrylic acid and energy costs
Specialty-grade margin	Higher than standard grade	Qualification and performance
Capital intensity	Moderate to high	Drying, polymerization, and environmental systems
Customer concentration	High in specialty grades	Limited qualified buyers
Working capital	Moderate	Inventory and qualification stock
R&D spending	Targeted	Low-monomer and medical-performance grades

Financial analysis should treat pharmaceutical-grade revenue as a premium niche, not as the principal market driver. A supplier’s valuation is more likely to track its total superabsorbent-polymer exposure, integration into acrylic acid, regional capacity, and contract structure.

How does this material compare with competing pharmaceutical polymers?

Excipient	Main advantage	Main limitation
Acrylic acid/sodium acrylate copolymer	High fluid absorption and swelling	Limited pharmaceutical standardization
Carbomer	Strong gel and rheology control	Sensitive to electrolytes and pH
Crospovidone	Established tablet disintegrant	Lower fluid-retention capability
Croscarmellose sodium	Broad regulatory familiarity	Less suitable for high-volume absorption
Sodium starch glycolate	Cost-effective disintegration	Performance varies with formulation
Hypromellose	Extensive controlled-release history	Does not provide comparable superabsorbency

The material has the strongest competitive position where absorption capacity is more important than conventional tablet disintegration. It is less competitive where formulators prioritize global compendial recognition, simple processing, and extensive regulatory precedent.

What geographic markets offer the strongest growth?

Asia-Pacific is the most important manufacturing and consumption region because it has substantial acrylic chemical capacity, large hygiene markets, and strong polymer production networks. Japan has established superabsorbent-polymer expertise. China has expanding capacity and competitive cost structures, although qualification and consistency vary by supplier. North America and Europe remain important for medical, pharmaceutical, and high-specification applications.

Geographic risk is concentrated in:

• Dependence on regional acrylic acid supply
• Shipping costs for high-volume absorbent materials
• Tariffs and trade restrictions
• Limited dual sourcing for pharmaceutical grades
• Site-change requirements after supply interruption
• Different residual-monomer and medical-device standards

A supplier with manufacturing in more than one region has a commercial advantage when customers require continuity of supply.

What licensing deals and partnerships affect the market?

Public licensing disclosures specifically covering pharmaceutical-grade acrylic acid/sodium acrylate copolymer are limited. The market relies more heavily on:

• Technology-transfer agreements
• Toll-manufacturing arrangements
• Long-term supply contracts
• Joint development with medical-device companies
• Customer-specific qualification programs
• Distribution agreements
• Confidential process licenses

Because the chemistry is mature, licensing value usually resides in process know-how, surface modification, particle engineering, or integration into a finished absorbent product. Contract terms, minimum-volume obligations, price-adjustment formulas, and change-control provisions can have greater economic importance than patent ownership.

What generic launch scenarios exist?

For a pharmaceutical or medical product using this polymer, four launch scenarios are relevant:

1. A competing product uses the same polymer grade from a second supplier.
2. A competitor uses a different polymer with comparable absorption or swelling.
3. The original supplier remains qualified while the product sponsor adds a second source.
4. A patent-protected formulation or device delays substitution despite the availability of unpatented polymer.

The fastest substitution pathway is usually supplier substitution within an established formulation. The slowest pathway is replacement of the polymer in a product where absorption, gel strength, skin compatibility, and stability are interdependent.

Key Takeaways

• Acrylic acid/sodium acrylate copolymer is primarily a superabsorbent polymer, not a high-volume conventional pharmaceutical excipient.
• Hygiene, wound care, continence products, and medical absorbents drive most industry economics.
• Pharmaceutical-grade demand is smaller but can command higher prices and stronger customer retention.
• No single Orange Book patent or exclusivity date governs the material.
• Patent protection is concentrated in crosslinking, particle structure, low-residual-monomer processes, and finished-product applications.
• Paragraph IV litigation is generally indirect and arises through drug, formulation, or device patents.
• Acrylic acid and energy prices are the main short-term margin variables.
• Qualification, regulatory documentation, and supply continuity are stronger entry barriers than basic composition patents.
• The most attractive strategy is to sell qualified specialty grades or engineered absorbent systems rather than undifferentiated polymer.
• Standalone pharmaceutical-excipient revenue is not publicly separated by major suppliers, making total superabsorbent-polymer exposure the more reliable financial metric.

FAQs

Is acrylic acid/sodium acrylate copolymer the same as sodium polyacrylate?

Often the terms are used commercially for closely related absorbent polymers, but they are not automatically identical. Copolymer composition, neutralization level, crosslinking, molecular weight, and residual monomer content must be compared grade by grade.

Can acrylic acid/sodium acrylate copolymer be used in tablets?

It can be used in selected formulations, but it is less established than crospovidone, croscarmellose sodium, and sodium starch glycolate. The formulation must address swelling, dissolution impact, compression behavior, and regulatory precedent.

Does FDA approve the excipient separately?

FDA generally reviews excipients through the finished drug application, inactive-ingredient precedent, drug master file documentation, and safety information. The supplier does not receive a universal approval covering every route or use.

Is the material protected by pharmaceutical patents?

The base polymer chemistry is mature. Active patent risk is more likely to involve a specific formulation, absorbent structure, manufacturing process, surface treatment, or drug-device combination.

What is the main investment risk?

The main risk is margin compression caused by acrylic acid and energy costs, excess superabsorbent-polymer capacity, limited pharmaceutical-grade demand, and customer substitution. Specialty qualification and medical applications can offset those risks but usually do not eliminate them.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
3. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
4. BASF SE. (2024). Annual report 2023. https://www.basf.com
5. Nippon Shokubai Co., Ltd. (2024). Integrated report 2024. https://www.shokubai.co.jp
6. Sumitomo Seika Chemicals Co., Ltd. (2024). Annual report and financial results materials. https://www.sumitomoseika.co.jp
7. International Pharmaceutical Excipients Council. (2017). Good manufacturing practices guide for pharmaceutical excipients. IPEC Federation.